• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Thursday, February 25, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Immunology

New class of synthetic molecules mimics antibodies

Bioengineer by Bioengineer
December 19, 2014
in Immunology, Synthetic Biology
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A Yale University lab has crafted the first synthetic molecules that have both the targeting and response functions of antibodies. The new molecules — synthetic antibody mimics (SyAMs) — attach themselves simultaneously to disease cells and disease-fighting cells. The result is a highly targeted immune response, similar to the action of natural human antibodies.

New class of synthetic molecules mimics antibodies

The new molecules — synthetic antibody mimics (SyAMs) — attach themselves simultaneously to disease cells and disease-fighting cells. The result is a highly targeted immune response, similar to the action of natural human antibodies. Photo Credit: Image courtesy of Yale University

“Unlike antibodies, however, our molecules are synthetic organic compounds that are approximately one-twentieth the size of antibodies,” said David A. Spiegel, a professor of chemistry at Yale whose lab developed the molecules. “They are unlikely to cause unwanted immune reactions due to their structure, are thermally stable, and have the potential to be administered orally, just like traditional, small-molecule drugs.”

Spiegel and his team describe the research in a paper published online Dec. 16 by the Journal of the American Chemical Society.

The paper looks specifically at SyAM molecules used to attack prostate cancer. Called SyAM-Ps, they work first by recognizing cancer cells and binding with a specific protein on their surface. Next, they also bind with a receptor on an immune cell. This induces a targeted response that leads to the destruction of the cancer cell.

Spiegel said the process of synthesizing and optimizing the structure of the molecules required considerable time and effort. “We now know that synthetic molecules of intermediate size possess perhaps the most important functional properties of antibodies — targeting and stimulation of immune cells,” he said.

“It’s also noteworthy that molecules of such a small size can bring together two objects as enormous as cells, and trigger a specific functional response, entirely as a result of specific receptor interactions,” Spiegel added.

Beyond their potential for treating prostate cancer, SyAMs may have applications for treating other forms of cancer, HIV and various bacterial diseases.

Story Source:

The above story is based on materials provided by Yale University, Jim Shelton.

Share12Tweet8Share2ShareShareShare2

Related Posts

IMAGE

Sulfur: the consequences

February 24, 2021
IMAGE

Human lung and brain organoids respond differently to SARS-CoV-2 infection in lab tests

February 24, 2021

COVID-19 vaccination axillary adenopathy detected during breast imaging

February 24, 2021

TBE patients’ lasting problems

February 23, 2021

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    Terahertz accelerates beyond 5G towards 6G

    637 shares
    Share 255 Tweet 159
  • People living with HIV face premature heart disease and barriers to care

    81 shares
    Share 32 Tweet 20
  • Global analysis suggests COVID-19 is seasonal

    37 shares
    Share 15 Tweet 9
  • HIV: an innovative therapeutic breakthrough to optimize the immune system

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

Infectious/Emerging DiseasesGeneticsChemistry/Physics/Materials SciencesCell BiologyPublic HealthTechnology/Engineering/Computer ScienceClimate ChangeMaterialscancerEcology/EnvironmentBiologyMedicine/Health

Recent Posts

  • How SARS-CoV-2’s sugar-coated shield helps activate the virus
  • Antibodies recognize and attack different SARS-CoV-2 spike shapes
  • Scientists reveal details of antibodies that work against Zika virus
  • Scientists uncover new details of SARS-CoV-2 interactions with human cells
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In